Group 1 - Definitive Healthcare announced the hiring of two senior leaders, Kate Hastings as Chief Customer Officer and Benjamin Graboske as EVP, Technology, Engineering and Chief Data Officer [1] - The Human Capital Management and Compensation Committee granted inducement awards consisting of 172,414 time-based restricted stock units (RSUs) to Hastings and 1,018,330 time-based RSUs to Graboske, effective March 3, 2025 [1] - The awards were individually negotiated and granted as an inducement material to the commencement of employment in accordance with Nasdaq Listing Rule 5635(c)(4) [1] Group 2 - Hastings' RSUs will vest 25% on February 1, 2026, with the remainder vesting in quarterly installments of 6.25% over the following three years [2] - Graboske's RSUs will vest 25% on April 1, 2026, with the remainder vesting in quarterly installments of 6.25% over the following three years [3] Group 3 - Definitive Healthcare focuses on transforming data, analytics, and expertise into healthcare commercial intelligence, helping clients identify markets, opportunities, and key personnel [4]

Financial Data and Key Metrics Changes - Total revenue for Q4 2024 was $62.3 million, down 6% year-over-year, reflecting customer retention challenges [7][38] - Adjusted EBITDA was $17.5 million, down 12% year-over-year, with an adjusted EBITDA margin of 28% [8][46] - Unlevered free cash flow was $72.5 million on a trailing 12-month basis, up 6% year-over-year [50] - Adjusted net income grew by 18% year-over-year, with non-GAAP earnings per share increasing by 19% [38] Business Line Data and Key Metrics Changes - Subscription revenue decreased by 4% year-over-year, while professional services revenue declined more significantly [39] - The company ended Q4 with 519 enterprise customers, a decrease of 21 year-over-year [40] - Net dollar retention for 2024 was 90% for enterprise customers and 85% overall [41] Market Data and Key Metrics Changes - Churn rates remained elevated, particularly in the life sciences sector, with downsells being a significant factor rather than outright losses [10][71] - The total customer count decreased to approximately 2,500, down about 250 from Q4 2023 [41] Company Strategy and Development Direction - The company is focusing on four key pillars: differentiated data, data delivery and integrations, driving customer success, and enabling digital engagement [16][63] - Strategic initiatives include combining sales channels and aligning customer success teams to improve retention and value delivery [14][31] - The company aims to enhance its master data management capabilities to better serve diverse customer needs [24][119] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that returning to growth will take longer than initially anticipated due to ongoing churn and macroeconomic conditions [30][63] - The company expects Q1 2025 to be a low point for revenue, with gradual improvement anticipated in subsequent quarters [55][79] - Guidance for 2025 includes a revenue forecast of $230 million to $240 million, reflecting a 5% to 9% decline year-over-year [60] Other Important Information - A $97 million goodwill impairment charge was recorded due to a decline in stock price, which is a non-cash accounting charge [54] - The company has amended its credit facilities to improve balance sheet efficiency, reducing total debt to $175 million [52] Q&A Session Summary Question: Can you provide more details on churn dynamics? - Management indicated that churn was more pronounced in life sciences, with Q4 churn being unfavorable compared to Q4 2023 [71][73] Question: Are you assuming that elongation in sales cycles persists in 2025? - Management expects Q1 to be challenging but anticipates sequential growth in Q2 due to a full quarterly revenue from a new data partnership [78][80] Question: What is embedded in the outlook regarding new customers versus upsell opportunities? - Recent performance has shown stronger results with new logos, while upsell opportunities face pricing pressure [85] Question: Have you seen a shift in marketing budgets from digital to in-person channels? - Management noted that while there is a macro environment affecting life sciences, they do not see a significant impact on their business from this shift [90][91] Question: Can you elaborate on why clients are downselling? - Management identified operational execution and pricing strategies as key areas to address customer needs and improve retention [99][101]

Financial Data and Key Metrics Changes - Total revenue for Q4 2024 was $62.3 million, down 6% year-over-year, reflecting customer retention challenges [8][39] - Adjusted EBITDA was $17.5 million, down 12% year-over-year, with an adjusted EBITDA margin of 28% [9][47] - Unlevered free cash flow was $72.5 million on a trailing 12-month basis, up 6% year-over-year [51] - Adjusted net income grew by 18% year-over-year, with non-GAAP earnings per share increasing by 19% [39] Business Line Data and Key Metrics Changes - Subscription revenue decreased by 4% year-over-year, while professional services revenue declined more significantly [40] - The company ended Q4 with 519 enterprise customers, a decrease of 21 year-over-year [41] - Net dollar retention for 2024 was 90% for enterprise customers and 85% overall [42] Market Data and Key Metrics Changes - The total customer count was approximately 2,500, down about 250 from Q4 2023 [42] - Churn rates remained elevated, particularly in the life sciences sector, impacting overall performance [11][72] Company Strategy and Development Direction - The company is focusing on four key pillars: differentiated data, data delivery and integrations, driving customer success, and enabling digital engagement [17][64] - Strategic initiatives include combining sales channels and aligning customer success teams to improve retention and value delivery [15][32] - The company aims to enhance its master data management capabilities to better serve diverse customer needs [25][100] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that improvements in retention and growth will take longer than initially anticipated [16][31] - The company expects Q1 2025 to be a low point for revenue, with gradual improvement anticipated throughout the year [56][80] - Guidance for 2025 indicates a revenue decline of 5% to 9% year-over-year, with expectations for sequential growth in Q2 [58][61] Other Important Information - A $97 million goodwill impairment charge was recorded due to stock price decline, which is a non-cash accounting charge [55] - The company has amended its credit facilities to improve balance sheet efficiency, reducing total debt [53] Q&A Session Summary Question: Can you provide more details on churn dynamics? - Management indicated that churn was more pronounced in life sciences, with Q4 churn being unfavorable compared to Q4 2023 [72][74] Question: Are you assuming elongation in the sales cycle for 2025? - Management expects Q1 to be challenging due to churn dynamics but anticipates revenue declines to moderate as the year progresses [80] Question: What is embedded in the outlook regarding new customers versus upsell opportunities? - Recent performance has shown stronger results with new logos, while upsell opportunities face pricing pressure [86] Question: Have you seen a shift in marketing budgets from digital to in-person channels? - Management noted that while there is a macro environment affecting life sciences, they do not see a significant impact on their business from this shift [91] Question: Can you elaborate on why clients are downselling? - Management identified operational execution and pricing strategies as key areas to address customer needs and improve retention [99][100]

Company Performance - Definitive Healthcare Corp. reported quarterly earnings of $0.08 per share, exceeding the Zacks Consensus Estimate of $0.07 per share, and showing an increase from $0.07 per share a year ago, resulting in an earnings surprise of 14.29% [1] - The company posted revenues of $62.29 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 3.02%, although this represents a decline from year-ago revenues of $65.93 million [2] - Over the last four quarters, the company has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Definitive Healthcare shares have increased approximately 24.1% since the beginning of the year, significantly outperforming the S&P 500's gain of 1.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.09 on revenues of $59.65 million, and for the current fiscal year, it is $0.30 on revenues of $241.89 million [7] Industry Outlook - The Internet - Software industry, to which Definitive Healthcare belongs, is currently ranked in the top 33% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40815 Definitive Healthcare Corp. (Exact name of Registrant as specified in its Charter) Delaware 86-3988281 (State or other jurisdic ...

Exhibit 99.1 Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2024 Fourth quarter and full year 2024 revenue exceeded guidance Framingham, MA (February 27, 2025) – Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights: Full Year 2024 Financial Highlights ...

Fourth quarter and full year 2024 revenue exceeded guidanceFRAMINGHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights: Revenue was $62.3 million, a decrease of 6% from $65.9 million in Q4 2023. Net Loss, inclusive of goodwill impairment charges ...

FRAMINGHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that its Chief Executive Officer, Kevin Coop, and its Chief Financial Officer, Rick Booth, will present at the Raymond James 2025 Institutional Investors Conference. The Definitive Healthcare presentation is scheduled for Tuesday, March 4, 2025, at 3:25 p.m. Eastern Time. A live webcast of the presentation will be a ...

FRAMINGHAM, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its fourth quarter and full year ended December 31, 2024, on Thursday, February 27, 2025 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company’s financial results. A live audio webcast of the event will ...

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .Today, we dive into Definitive Healthcare Corp. (NASDAQ: DH ) for the first time. This SaaS-enabled technology solution company is focused on the healthcare industry. On a P/E basi ...